Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2013 by Seoul National University Hospital
Sponsor:
Information provided by (Responsible Party):
Seoul National University Hospital
ClinicalTrials.gov Identifier:
NCT01765010
First received: January 8, 2013
Last updated: NA
Last verified: January 2013
History: No changes posted
  Purpose

The purpose of this study is to compare the effect of inactive and active vitamin D on serum sclerostin and dickkopf1 levels.


Condition Intervention Phase
Osteoporosis
Drug: Calcitriol
Drug: Alfacalcidol
Drug: Cholecalciferol
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels

Resource links provided by NLM:


Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • Change of serum sclerostin level [ Time Frame: 8 weeks later ] [ Designated as safety issue: No ]
  • Change of serum Dickkopf1 level [ Time Frame: 8 weeks later ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change of serum c-telopeptide level [ Time Frame: 8 weeks later ] [ Designated as safety issue: No ]
  • Change of serum bone-specific alkaline phosphatase level [ Time Frame: 8 weeks later ] [ Designated as safety issue: No ]
  • Change of serum calcium level [ Time Frame: 8 weeks later ] [ Designated as safety issue: Yes ]
  • Change of serum parathyroid hormone level [ Time Frame: 8 weeks later ] [ Designated as safety issue: No ]

Estimated Enrollment: 88
Study Start Date: January 2013
Estimated Study Completion Date: March 2013
Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo control
Placebo control
Drug: Placebo
Other Name: placebo
Active Comparator: Cholecalciferol 1000IU
Cholecalciferol 1000IU qd for 8 weeks
Drug: Cholecalciferol
Other Name: DicamaxD
Experimental: alfacalcidol
alfacalcidol 0.5ug qd for 8 weeks
Drug: Alfacalcidol
Other Name: Onealfa
Experimental: Calcitriol
Calcitriol 0.25ug qd for 8 weeks
Drug: Calcitriol
Other Name: Calcio

  Eligibility

Ages Eligible for Study:   20 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male volunteer older than 20 years

Exclusion Criteria:

  • Subjects with bone and mineral metabolism disorders
  • Subjects with kidney or liver diseases
  • Subjects with uncorrectable hypercalcemia or hypocalcemia
  • Subjects with chronic gastrointestinal disorders or malabsorption
  • Subjects taking medication related to bone loss
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01765010

Contacts
Contact: Chan Soo Shin, MD, PhD +82-2-2072-3734 csshin@snu.ac.kr
Contact: Jung Hee Kim, MD +82-2-2072-4839 jhkxingfu@gmail.com

Locations
Korea, Republic of
Seoul National University Medical School Recruiting
Seoul, Korea, Republic of, 110-744
Contact: Chan Soo Shin, MD, PhD    82220723734    csshin@snu.ac.kr   
Contact: Jung Hee Kim, MD    8220724839    jhkxingfu@gmail.com   
Principal Investigator: Chan Soo Shin, MD, PhD         
Sponsors and Collaborators
Seoul National University Hospital
Investigators
Principal Investigator: Chan Soo Shin, MD, PhD Seoul National University Medical School
  More Information

No publications provided

Responsible Party: Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT01765010     History of Changes
Other Study ID Numbers: SNUH-ENDO-2013
Study First Received: January 8, 2013
Last Updated: January 8, 2013
Health Authority: Korea: Food and Drug Administration
Korea: Ministry for Health and Welfare

Keywords provided by Seoul National University Hospital:
Vitamin D
Serum sclerostin
Serum dickkopf1

Additional relevant MeSH terms:
Osteoporosis
Bone Diseases
Bone Diseases, Metabolic
Musculoskeletal Diseases
Alfacalcidol
Calcitriol
Cholecalciferol
Hydroxycholecalciferols
Vitamin D
Vitamins
Bone Density Conservation Agents
Calcium Channel Agonists
Cardiovascular Agents
Growth Substances
Membrane Transport Modulators
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vasoconstrictor Agents

ClinicalTrials.gov processed this record on November 24, 2014